Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-20-054246
Date:2020-10-05
Issuer: ADURO BIOTECH, INC. (KDNY)
Original Submission Date:

Reporting Person:

FROHLICH TOM
C/O CHINOOK THERAPEUTICS, INC.
1600 FAIRVIEW AVE. E. SEATTLE, WA 98102

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-10-05 A 153,398 a $0.00 153,398 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 0.42 2020-10-05 deemed execution date A 98,847 (a) 2030-03-17 common stock 98,847 $0.42 98,847 direct
STOCK OPTION (RIGHT TO BUY) 14.77 2020-10-06 deemed execution date A 119,793 (a) 2030-10-05 common stock 119,793 $14.77 119,793 direct
RESTRICTED STOCK UNITS (RSU) (COMMON STOCK) 0.0 2020-10-06 deemed execution date A 40,743 (a) 2030-10-05 common stock 40,743 $0.00 40,743 direct
Footnotes
IDfootnote
f1 certain of the shares are subject to forfeiture to the issuer if underlying vesting conditions are not met.
f2 the shares reported represent the number of shares of issuer common stock received by the reporting person on the effective date in connection with the merger of chinook therapeutics u.s., inc. ("private chinook") into the issuer.
f3 the stock option vests as to 25% of the total shares on march 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fullyvested, subject to the reporting person's provision of service to the issuer on each vesting date.
f4 received in connection with the merger of private chinook into the issuer in exchange for a stock option to acquire 338,300shares of private chinook common stock for $0.12 per share.
f5 the stock option vests as to 25% of the total shares on october 6, 2021, and thereafter vests as to 1/36 of the total shares monthly until fully vested, subject to the reporting person's provision of service to the issuer on each vesting date.
f6 each restricted stock unit represents a contingent right to receive one share of issuer's common stock.
f7 the rsus vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on october 6, 2021, until fully vested subject to the reporting person's provision of service to the issuer on each vesting date.
WhaleWisdom Logo

Elevate your investments